Raloxifene is a selective estrogen receptor modulator (SERM) used to treat and prevent osteoporosis in postmenopausal women, and reduce the risk of invasive breast cancer in both postmenopausal women with osteoporosis and those at high risk for breast cancer. It mimics estrogen’s beneficial effects on bone density, aiding in bone strength maintenance.
Evista, generically known as raloxifene, is a medication used to prevent and treat osteoporosis in postmenopausal women. It mimics estrogen’s effects on bones, aiding in maintaining bone density and reducing fractures. Additionally, Evista lowers the risk of invasive breast cancer, especially in women with osteoporosis or high cancer risk. As a selective estrogen receptor modulator (SERM), it offers estrogen benefits in some tissues while blocking effects in others, like the breast. Common side effects include hot flashes, leg cramps, and an increased risk of blood clots, making thorough health discussions crucial.
Evista, known generically as raloxifene, is primarily used for preventing and treating osteoporosis in postmenopausal women. As a selective estrogen receptor modulator (SERM), it mimics estrogen’s positive effects on bone density, reducing fracture risk and enhancing skeletal health. Evista also lowers the risk of invasive breast cancer in postmenopausal women with osteoporosis or high breast cancer risk, offering multifaceted benefits. Consulting healthcare providers ensures suitability and addresses potential side effects for users effectively.
